Compare Gilead Sciences, Inc. (GILD) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Ulta Beauty Inc — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Ulta Beauty Inc trades at $570.37 (market cap $24.12B). The key difference: Gilead Sciences, Inc. is far larger — about 7.6× Ulta Beauty Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Ulta Beauty Inc for 92 Days on average.
| GILD | ULTA | |
|---|---|---|
Market Cap | $182.40B | $24.12B |
Volume | 4,469,821 | 457,598 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $706.82 |
52-Week Low | $117.18 | $450.75 |
Typical Hold Time | 111 Days | 92 Days |
Enterprise Value | $205.46B | $26.43B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
ULTA stock trades at $564.21, up 3.43% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 outlook, driven by e-commerce momentum. Valuation metrics like a P/E of 20.55 and P/S of 1.92 appear reasonable relative to high profitability, including a 46.12% ROE. The stock is near its pivot point of $563, with resistance at $568.
The outlook is positive, with growth opportunities in private label, wellness categories, and international expansion. Risks include margin pressure from promotions and flat store traffic. With 59.57% of analysts rating it Buy and a consensus price target of $624.93, the stock offers upside potential, but execution on guidance is critical for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
